Prof. Michael Sela
member of the Scientific Advisory Board
Pharmaceuticals
Silenseed
Israel
Biography
Prof. Michael Sela has been a member of the Scientific Advisory Board at DeveloGen AG since June 1, 2005. He is also a Member of Scientific Advisory Board at Rosetta Genomics. He has been a Director of Teva Pharmaceutical Industries Ltd. since 1987. Prof. Sela served as former President of the Weizmann Institute of Science in Rehovot, Israel, and Chief Immunologist at the New England Medical Center in Boston, USA. He has held visiting professorships at the Tufts University School of Medicine in Boston, at the Massachusetts Institute of Technology in Cambridge, and at the Institute Pasteur in Paris, France. Prof. Sela received, among others, the Doctorate Honoris Causa of the Ben-Gurion University of the Negev, the University of Tel-Aviv and the Hebrew University of Jerusalem. He received his Ph.D. degree in Biochemistry from Hebrew University in 1954. Prof Sela developed two leading drugs: a copolymer which became a major multiple sclerosis medication. Produced by Teva Pharmaceuticals Ltd. under the name Copaxone®, it has been approved for marketing in United States and Europe; in addition, he developed a monoclonal antibody for the treatment of colorectal, head and neck cancer. The antibody is marketed under the name Erbitux® worldwide.
Research Interest
multiple sclerosis medication
